GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Millendo Therapeutics Inc (NAS:MLND) » Definitions » Revenue per Share

Millendo Therapeutics (Millendo Therapeutics) Revenue per Share : $0.00 (TTM As of Mar. 2021)


View and export this data going back to 2012. Start your Free Trial

What is Millendo Therapeutics Revenue per Share?

Millendo Therapeutics's revenue per share for the three months ended in Mar. 2021 was $0.00. Millendo Therapeutics's revenue per share for the trailing twelve months (TTM) ended in Mar. 2021 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Millendo Therapeutics's Revenue per Share or its related term are showing as below:

MLND's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.7
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

Millendo Therapeutics Revenue per Share Historical Data

The historical data trend for Millendo Therapeutics's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Millendo Therapeutics Revenue per Share Chart

Millendo Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.57 1.86 - - -

Millendo Therapeutics Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Millendo Therapeutics's Revenue per Share

For the Biotechnology subindustry, Millendo Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Millendo Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Millendo Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Millendo Therapeutics's PS Ratio falls into.



Millendo Therapeutics Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Millendo Therapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2020 is calculated as

Revenue Per Share (A: Dec. 2020 )=Revenue (A: Dec. 2020 )/Shares Outstanding (Diluted Average) (A: Dec. 2020 )
=0/1.258
=0.00

Millendo Therapeutics's Revenue Per Share for the quarter that ended in Mar. 2021 is calculated as

Revenue Per Share (Q: Mar. 2021 )=Revenue (Q: Mar. 2021 )/Shares Outstanding (Diluted Average) (Q: Mar. 2021 )
=0/1.268
=0.00

Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Millendo Therapeutics  (NAS:MLND) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Millendo Therapeutics Revenue per Share Related Terms

Thank you for viewing the detailed overview of Millendo Therapeutics's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Millendo Therapeutics (Millendo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
110 Miller Avenue, Suite 100, Ann Arbor, MI, USA, 48104
Millendo Therapeutics Inc is a biopharmaceutical company.
Executives
Mary Lynne Hedley director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Howe John P Md director C/O BB&T, P O BOX 1250, WINSTON SALEM NC 27102-1250
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Carole Nuechterlein director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Geoffrey Nichol director MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
James M. Hindman director 2525 DUPONT DRIVE, IRVINE CA 92612
Christophe Arbet-engels officer: Chief Medical Officer C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Ryan Zeidan officer: Chief Development Officer C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Julia C. Owens director, officer: President and CEO C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451
Tamara L Joseph officer: General Counsel and Secretary 32 GARRISON STREET, APT 50-103, BOSTON MA 02116
Arcudi Iii Louis J officer: Chief Financial Officer C/O IDERA PHARMACEUTICALS 167 SYDNEY ST, CAMBRIDGE MA 02139
Randall W Whitcomb director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Jeffery M. Brinza officer: Sec., CAO and General Counsel C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451
Pharis Mohideen officer: Chief Medical Officer C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451

Millendo Therapeutics (Millendo Therapeutics) Headlines